Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Sept 23 (Reuters) - Seres Therapeutics Inc MCRB.O:
SERES THERAPEUTICS ANNOUNCES FURTHER CONSTRUCTIVE FEEDBACK FROM FDA ON SER-155 PHASE 2 STUDY PROTOCOL AND IMPLEMENTS COST REDUCTION ACTIONS TO EXTEND CASH RUNWAY
SERES THERAPEUTICS INC - REDUCES WORKFORCE BY 25% TO EXTEND CASH RUNWAY
SERES THERAPEUTICS INC - WORKFORCE REDUCTION TO RESULT IN $1.0-$1.4 MILLION SEVERANCE COSTS
SERES THERAPEUTICS INC - SEEKS CAPITAL TO ADVANCE SER-155 PHASE 2 STUDY
SERES THERAPEUTICS INC: EXPECTS TO EXTEND CASH RUNWAY WELL INTO Q2 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Trump Administration Brokers. Intel and Apple Reach Chipmaking Agreement, Shares Surge More Than 13%

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Navitas Stock’s AI Data Center Pivot: Up 88% YTD—Is NVTS Stock Still a Buy?

Tradingkey







